Vasaprostane, lyophilizate 20 mcg 48.2 mg 10 pcs

Vasaprostane is a vasodilator, antiaggregative.

Vasaprostane is a drug of prostaglandin E1. It improves microcirculation and peripheral circulation.

Limits arterioles and postcapillary sphincters tone, decreases PPS with no change in BP, increases coronary blood flow and left ventricular ejection fraction.

It improves rheological properties of blood by reducing platelet adhesion and aggregation, reducing aggregation and improving erythrocyte deformability, increasing fibrinolytic activity and reducing blood viscosity.

It affects the metabolism, increases glucose and oxygen utilization, inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates protein synthesis, has a beneficial effect on lipid metabolism (inhibition of cholesterol synthesis and reduction of LDL concentration), inhibits proliferation and mitosis of smooth muscle cells.

With Vasaprostan treatment the severity of pain at rest decreases, the healing of trophic ulcers accelerates, remission of the disease occurs.

Indications

Microcirculatory disorders

Treatment of chronic obliterating arterial diseases of stages III and IV.

Active ingredient

Alprostadil

Composition

1 ampoule contains alprostadil (in the form of alpha-cyclodextrin) 20 mcg;

excipients:

Lactose;

Alfadex.

How to take, the dosage

Vasaprostane can be administered w/a and intravenously.

To obtain a solution for intra-arterial administration, 20 mcg (the contents of one ampoule) should be dissolved in 50 ml of physiological solution. For intra-arterial infusion, 25 ml of the resulting solution (10 mcg alprostadil) should be administered for 60-120 minutes using a special device for intra-arterial infusion. If necessary (especially for necrosis), the dose can be increased to 50 ml (20 mcg). If the drug is administered through an indwelling catheter, the IV infusion is given for 12 hours at a dose of 0.1-0.6 ng/kg body weight per minute (corresponding to 12.5-25 ml of Vasaprostane solution).

To obtain a solution for intravenous administration, 40 mcg (the contents of two ampoules) of the dry substance should be dissolved in 50-250 ml of physiological solution and the resulting solution should be infused by IV drip for 2 hours 2 times a day, or 60 mcg (the contents of 3 ampoules) should be dissolved in 50-250 ml of physiological solution and infused by IV drip for 3 hours 1 time/day.

In patients with impaired renal function (creatinine concentration more than 1.5 mg/dL), Vazaprostane should be started with 10 mg twice daily, the duration of each infusion is 2 hours. If tolerated well, within 2-3 days the dose can be increased to the usual one. Duration of one course of treatment should not exceed 4 weeks.

Interaction

In concomitant use Vasaprostan may increase the hypotensive effect of antihypertensive drugs, peripheral vasodilators, antianginal drugs.

When Vasaprostan is used concomitantly with anticoagulants, antiaggregants the possibility of hemorrhagic syndrome increases.

Special Instructions

With Vasaprostan treatment, patients with signs of renal and cardiac insufficiency should limit fluid volume to 50-100 ml/day.

In the course of therapy BP, HR should be monitored, if necessary – fluid balance control, central venous pressure measurement, EchoCG should be performed. Clinical efficacy of treatment is evaluated after 3 weeks of therapy.

With Vasaprostan therapy C-reactive protein may show up during biochemical blood tests.

Contraindications

– Chronic heart failure in decompensation stage;
– Acute myocardial infarction and postinfarction period within 6 months;
– Severe heart rhythm disorders;
– acute circulatory insufficiency (shock, vascular collapse);
– severe arterial hypotension (systolic BP less than 90 mm Hg).Severe arterial hypotension (systolic blood pressure less than 90 mm Hg);
– Expressed liver function impairment;
– Gastric and duodenal ulcer;
– Hypersensitivity to the preparation.

Side effects

Cardiovascular system: palpitation, arterial hypotension, headache; in single cases – frequent attacks of angina, development of pulmonary edema, heart failure.

Digestive system disorders: dyspeptic complaints, increased liver transaminase activity.

Other: leukopenia, leukocytosis; in prolonged therapy (more than 4 weeks) in single cases of hyperostosis of tubular bones.

Local reactions: swelling, hyperemia, pain at the injection site.

Overdose

Symptoms: decreased BP, skin hyperemia, weakness.

Treatment: the drug infusion should be slowed or stopped; if necessary, symptomatic therapy is carried out.

Similarities

Caverject